Product Description
Emalex Biosciences is developing Ecopipam as a treatment for Tourette's and other central nervous system disorders. (Sourced from: https://emalexbiosciences.com/research-development/#drug-pipeline)
Mechanisms of Action: D1 Antagonist, D5 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Emalex Biosciences
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Canada, Denmark, France, Germany, Hungary, Italy, Poland, Romania, Serbia, Spain, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Other|Rett Syndrome|Tourette Syndrome
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-503545-67-00 |
EBS-101-TD-391 | P3 |
Recruiting |
Other |
2027-04-13 |
16% |
2025-05-02 |
Treatments |
NCT06021522 |
EBS-101-TD-391 | P3 |
Active, not recruiting |
Rett Syndrome|Tourette Syndrome |
2026-12-01 |
16% |
2025-08-14 |
Primary Endpoints|Treatments|Trial Status |
NCT05841160 |
EBS-101-HV-105 | P1 |
Completed |
Healthy Volunteers |
2023-05-07 |
69% |
2024-11-27 |
|
NCT06669091 |
EBS-101-HV-107 | P1 |
Completed |
Healthy Volunteers |
2024-12-22 |
88% |
2025-01-28 |
|
NCT05615220 |
D1AMOND | P3 |
Completed |
Rett Syndrome|Tourette Syndrome |
2025-01-13 |
18% |
2025-05-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
2023-503494-38-00 |
EBS-101-TD-301 | P3 |
Completed |
Other |
2025-01-16 |
2025-05-02 |
||
NCT06194864 |
EBS-101-HV-106 | P1 |
Completed |
Healthy Volunteers |
2024-05-14 |
12% |
2024-08-29 |